Use of soluble CD26 as inhibitor of angiogenesis and inflammation
OwnerChiwen Changinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to soluble CD26 or a biologically active variant of the soluble CD26 that effectively inhibits angiogenesis and inflammation in a mammalian subject, pharmaceutical compositions comprising the soluble CD26 and the use of soluble CD26 in methods of treatment.
Claims29
A method of inhibiting VEGF activity, comprising contacting VEGF with an effective amount of soluble CD26 or a biologically active variant of soluble CD26.
A method of inhibiting angiogenesis in a mammalian subject, comprising administering to said subject a therapeutically effective amount of soluble CD26 or a biologically active variant of soluble CD26.
A method of treating a disease or a condition associated with angiogenesis in a mammalian subject, comprising administering to said subject a therapeutically effective amount of soluble CD26 or a biologically active variant of soluble CD26.
A method of inactivating VEGF comprising cleaving said VEGF after a recognition motif sequence.
A pharmaceutical composition comprising soluble CD26 or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier.
A method of inhibiting IL-2 activity, comprising contacting IL-2 with an effective amount of soluble CD26 or a biologically active variant of soluble CD26.
A method of inactivating IL-2 comprising cleaving said IL-2 after a recognition motif sequence.
A method of inhibiting inflammation in a mammalian subject, comprising administering to said subject a therapeutically effective amount of soluble CD26 or a biologically active variant of soluble CD26.
A method for the treatment of an inflammatory, immune or autoimmune disease in a mammalian subject, comprising administering to said subject a therapeutically effective amount of soluble CD26 or a biologically active variant of soluble CD26.
An antagonist antibody that specifically binds to and inhibits soluble CD26 or a biologically active variant of soluble CD26.
Dependencies are inferred from the claim text.